Extracellular vesicles derived from starving BMSCs enhance survival of chondrocyte aggregates in grafts by attenuating chondrocyte apoptosis and enabling stable cartilage regeneration for craniofacial reconstruction

Yuan, Pingping; Li, Zhiye; Shao, Bo; Tian, Ziqiang; Wu, Xiaopeng; Wang, Yinggang; Zhao, Yimin; Wu, Wei

doi:10.1016/j.actbio.2021.12.011

Cited by 13 publications

(5 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, BMSCs can also enhance the survival and chondrogenic capacity of chondrocytes. Yuan injected extracellular vesicles (EVs) secreted by BMSCs into the nasal cavities of mice and observed that EVs could suppress chondrocyte apoptosis through miRNAs, improving chondrocyte survival under ischemic conditions ( Yuan et al, 2022 ).…”

Section: Bone Marrow Mesenchymal Stem Cellsmentioning

confidence: 99%

Mesenchymal stem cells in craniofacial reconstruction: a comprehensive review

Zheng,

Liu,

Liu

et al. 2024

Front. Mol. Biosci.

View full text Add to dashboard Cite

Craniofacial reconstruction faces many challenges, including high complexity, strong specificity, severe injury, irregular and complex wounds, and high risk of bleeding. Traditionally, the “gold standard” for treating craniofacial bone defects has been tissue transplantation, which involves the transplantation of bone, cartilage, skin, and other tissues from other parts of the body. However, the shape of craniofacial bone and cartilage structures varies greatly and is distinctly different from ordinary long bones. Craniofacial bones originate from the neural crest, while long bones originate from the mesoderm. These factors contribute to the poor effectiveness of tissue transplantation in repairing craniofacial defects. Autologous mesenchymal stem cell transplantation exhibits excellent pluripotency, low immunogenicity, and minimally invasive properties, and is considered a potential alternative to tissue transplantation for treating craniofacial defects. Researchers have found that both craniofacial-specific mesenchymal stem cells and mesenchymal stem cells from other parts of the body have significant effects on the restoration and reconstruction of craniofacial bones, cartilage, wounds, and adipose tissue. In addition, the continuous development and application of tissue engineering technology provide new ideas for craniofacial repair. With the continuous exploration of mesenchymal stem cells by researchers and the continuous development of tissue engineering technology, the use of autologous mesenchymal stem cell transplantation for craniofacial reconstruction has gradually been accepted and promoted. This article will review the applications of various types of mesenchymal stem cells and related tissue engineering in craniofacial repair and reconstruction.

show abstract

Section: Bone Marrow Mesenchymal Stem Cellsmentioning

confidence: 99%

Mesenchymal stem cells in craniofacial reconstruction: a comprehensive review

Zheng,

Liu,

Liu

et al. 2024

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…BMSC-EVs also alter the process of bone regeneration partially by regulating the level of autophagy, although the exact mechanism remains unclear. Fortunately, BMSC-EVs have been shown to inhibit nucleus pulposus (NP) cell apoptosis, ameliorate IVDD [ 139 ], and improve chondrocyte survival [ 140 ] by enhancing autophagy flux. These studies provide new insights into how BMSC-EVs can improve cellular function, cartilage reconstruction, and disease, further indicating the importance of BMSC autophagy regulation in bone regeneration.…”

Section: Therapeutic Approaches For Bone Diseases By Modulating Autop...mentioning

confidence: 99%

The role of autophagy in bone metabolism and clinical significance

et al. 2023

View full text Add to dashboard Cite

The skeletal system is the basis of the vertebral body composition, which affords stabilization sites for muscle attachment, protects vital organs, stores mineral ions, supplies places to the hematopoietic system, and participates in complex endocrine and immune system. Not surprisingly, bones are constantly reabsorbed, formed, and remodeled under physiological conditions. Once bone metabolic homeostasis is interrupted (including inflammation, tumors, fractures, and bone metabolic diseases), the body rapidly initiates bone regeneration to maintain bone tissue structure and quality. Macroautophagy/autophagy is an essential metabolic process in eukaryotic cells, which maintains metabolic energy homeostasis and plays a vital role in bone regeneration by controlling molecular degradation and organelle renewal. One relatively new observation is that mesenchymal cells, osteoblasts, osteoclasts, osteocytes, chondrocytes, and vascularization process exhibit autophagy, and the molecular mechanisms and targets involved are being explored and updated. The role of autophagy is also emerging in degenerative diseases (intervertebral disc degeneration [IVDD], osteoarthritis [OA], etc.) and bone metabolic diseases (osteoporosis [OP], osteitis deformans, osteosclerosis). The use of autophagy regulators to modulate autophagy has benefited bone regeneration, including MTOR (mechanistic target of rapamycin kinase) inhibitors, AMPK activators, and emerging phytochemicals. The application of biomaterials (especially nanomaterials) to trigger autophagy is also an attractive research direction, which can exert superior therapeutic properties from the material-loaded molecules/drugs or the material’s properties such as shape, roughness, surface chemistry, etc. All of these have essential clinical significance with the discovery of autophagy associated signals, pathways, mechanisms, and treatments in bone diseases in the future. Abbreviations: Δψm: mitochondrial transmembrane potential AMPK: AMP-activated protein kinase ARO: autosomal recessive osteosclerosis ATF4: activating transcription factor 4 ATG: autophagy-related β-ECD: β-ecdysone BMSC: bone marrow mesenchymal stem cell ER: endoplasmic reticulum FOXO: forkhead box O GC: glucocorticoid HIF1A/HIF-1α: hypoxia inducible factor 1 subunit alpha HSC: hematopoietic stem cell HSP: heat shock protein IGF1: insulin like growth factor 1 IL1B/IL-1β: interleukin 1 beta IVDD: intervertebral disc degradation LPS: lipopolysaccharide MAPK: mitogen-activated protein kinase MSC: mesenchymal stem cell MTOR: mechanistic target of rapamycin kinase NP: nucleus pulposus NPWT: negative pressure wound therapy OA: osteoarthritis OP: osteoporosis PTH: parathyroid hormone ROS: reactive oxygen species SIRT1: sirtuin 1 SIRT3: sirtuin 3 SQSTM1/p62: sequestosome 1 TNFRSF11B/OPG: TNF receptor superfamily member 11b TNFRSF11A/RANK: tumor necrosis factor receptor superfamily, member 11a TNFSF11/RANKL: tumor necrosis factor (ligand) superfamily, member 11 TSC1: tuberou...

show abstract

“… 73 – 75 MSCs foster a regenerative microenvironment by secreting a broad spectrum of paracrine factors including MSC-EVs. 76 MSC-EVs have been verified to enhance bone formation as shown in significantly increased osteogenic gene expression like type I collagen (COL I), alkaline phosphatase (ALP), osteocalcin (OCN), and osteopontin (OPN). 77 In MSC-EVs, the pro-osteogenic microRNAs such as miR-10b and miR-21 are increased, while the anti-osteogenic microRNAs like miR-31, miR-144, and miR-221 are decreased.…”

Section: Msc Transplantationmentioning

confidence: 99%

Cell-based therapies for rheumatoid arthritis: opportunities and challenges

Chen

2022

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is the most common immune-mediated inflammatory disease characterized by chronic synovitis that hardly resolves spontaneously. The current treatment of RA consists of nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, conventional disease-modifying antirheumatic drugs (cDMARDs), biologic and targeted synthetic DMARDs. Although the treat-to-target strategy has been intensively applied in the past decade, clinical unmet needs still exist since a substantial proportion of patients are refractory or even develop severe adverse effects to current therapies. In recent years, with the deeper understanding of immunopathogenesis of the disease, cell-based therapies have exhibited effective and promising interventions to RA. Several cell-based therapies, such as mesenchymal stem cells (MSC), adoptive transfer of regulatory T cells (Treg), and chimeric antigen receptor (CAR)-T cell therapy as well as their beneficial effects have been documented and verified so far. In this review, we summarize the current evidence and discuss the prospect as well as challenges for these three types of cellular therapies in RA.

show abstract

Extracellular vesicles derived from starving BMSCs enhance survival of chondrocyte aggregates in grafts by attenuating chondrocyte apoptosis and enabling stable cartilage regeneration for craniofacial reconstruction

Cited by 13 publications

References 52 publications

Mesenchymal stem cells in craniofacial reconstruction: a comprehensive review

Mesenchymal stem cells in craniofacial reconstruction: a comprehensive review

The role of autophagy in bone metabolism and clinical significance

Cell-based therapies for rheumatoid arthritis: opportunities and challenges

Contact Info

Product

Resources

About